Sutro Biopharma, Inc.(STRO)

Description: Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

---

Keywords: Medicine Cancer Clinical Medicine Biology Immunology Antibodies Drug Discovery Cancer Treatment Lymphoma Antineoplastic Drugs Multiple Myeloma Autoimmune Disorders Immune Disorders Endometrial Cancer Immunogen Non Hodgkin Lymphoma Hodgkin Lymphoma Therapeutics For Cancer Milatuzumab Ovarian And Endometrial Cancers

---

Home Page: www.sutrobio.com

STRO Technical Analysis

111 Oyster Point Boulevard
South San Francisco, CA 94080
United States
Phone: 650 881 6500

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)